Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03, Zacks reports.
Acurx Pharmaceuticals Trading Down 3.9%
NASDAQ:ACXP opened at $0.38 on Wednesday. The stock has a 50 day moving average of $0.39 and a 200-day moving average of $0.80. The firm has a market capitalization of $8.51 million, a PE ratio of -0.35 and a beta of -1.37. Acurx Pharmaceuticals has a 52 week low of $0.30 and a 52 week high of $3.33.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Acurx Pharmaceuticals in a report on Wednesday, March 19th.
Acurx Pharmaceuticals Company Profile
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Featured Articles
- Five stocks we like better than Acurx Pharmaceuticals
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Tesla: Get Ready To See It Trading Above $400 Again
- Want to Profit on the Downtrend? Downtrends, Explained.
- ON Holding Surges, Leads High-End Retailers Into Reversal
- Most Volatile Stocks, What Investors Need to Know
- NVIDIA Stock Surges on Bullish News: How High Could It Climb?
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
